[go: up one dir, main page]

WO1999038524A3 - Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs - Google Patents

Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs Download PDF

Info

Publication number
WO1999038524A3
WO1999038524A3 PCT/IB1999/000149 IB9900149W WO9938524A3 WO 1999038524 A3 WO1999038524 A3 WO 1999038524A3 IB 9900149 W IB9900149 W IB 9900149W WO 9938524 A3 WO9938524 A3 WO 9938524A3
Authority
WO
WIPO (PCT)
Prior art keywords
low density
density lipoprotein
lipoprotein receptor
immune regulation
ldl
Prior art date
Application number
PCT/IB1999/000149
Other languages
English (en)
Other versions
WO1999038524A2 (fr
Inventor
Patrick Thomas Prendergast
Original Assignee
Patrick Thomas Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Thomas Prendergast filed Critical Patrick Thomas Prendergast
Priority to AU20697/99A priority Critical patent/AU2069799A/en
Publication of WO1999038524A2 publication Critical patent/WO1999038524A2/fr
Publication of WO1999038524A3 publication Critical patent/WO1999038524A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'administration du récepteur des lipoprotéines humaines et animales de faible densité (LDL-R) développe une activité anti-VIH et anti-hépatite significative. Dans la variante préférée, l'invention a trait à l'activité anti virale et régulatrice de l'immunité du domaine riche en cystéine du LDL-R. Lesdits LDL-R, d'origine humaine et animale, qui s'administrent dans le traitement d'infections virales et comme agent régulateur de l'immunité, entrent dans la fabrication de médicaments à cet effet.
PCT/IB1999/000149 1998-01-29 1999-01-28 Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs WO1999038524A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20697/99A AU2069799A (en) 1998-01-29 1999-01-28 Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7298098P 1998-01-29 1998-01-29
US60/072,980 1998-01-29

Publications (2)

Publication Number Publication Date
WO1999038524A2 WO1999038524A2 (fr) 1999-08-05
WO1999038524A3 true WO1999038524A3 (fr) 1999-09-23

Family

ID=22110978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/000149 WO1999038524A2 (fr) 1998-01-29 1999-01-28 Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs

Country Status (3)

Country Link
AU (1) AU2069799A (fr)
WO (1) WO1999038524A2 (fr)
ZA (1) ZA99719B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1111040A1 (fr) * 1999-12-10 2001-06-27 Daniel Favre L'infection de cellules eukaryotes par des virus in vitro
WO2001047545A1 (fr) * 1999-12-28 2001-07-05 Sumitomo Pharmaceuticals Company, Limited Produits therapeutiques et prophylactiques pour l'hepatique chronique
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法
IL188628A0 (en) * 2008-01-07 2008-12-29 Yeda Res & Dev Use of soluble ldl-r for viral hepatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02157229A (ja) * 1988-12-07 1990-06-18 Nitto Denko Corp 免疫抑制剤
EP0553667A1 (fr) * 1992-01-19 1993-08-04 Yeda Research And Development Company Limited Récepteur à LDL-soluble, sa production et son utilisation
DE4222385A1 (de) * 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02157229A (ja) * 1988-12-07 1990-06-18 Nitto Denko Corp 免疫抑制剤
EP0553667A1 (fr) * 1992-01-19 1993-08-04 Yeda Research And Development Company Limited Récepteur à LDL-soluble, sa production et son utilisation
DE4222385A1 (de) * 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISCHER D G ET AL: "Isolation and characterization of a soluble form of the LDL receptor, an interferon-induced antiviral protein.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1994 JUL) 206 (3) 228-32., XP002110889 *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 417 (C - 0756) 10 September 1990 (1990-09-10) *

Also Published As

Publication number Publication date
ZA99719B (en) 1999-10-22
WO1999038524A2 (fr) 1999-08-05
AU2069799A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
EP1852121A3 (fr) Analogues de lipides pour traiter des infections virales
IL112667A (en) 6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
CA2293470A1 (fr) Derives de benzimidazole
AP9901661A0 (en) Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
CA2139385A1 (fr) Produits renfermant une proteine liante de g-csf et de tnf
JP2002523437A5 (fr)
James DOXIL approved for KS
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
WO2001089537A3 (fr) Entites apoptotiques s'utilisant dans le traitement des troubles neurodegeneratifs et autres troubles neurologiques
WO1999038524A3 (fr) Administration de ldl-r a des fins therapeutiques contre les infections virales et comme immunoregulateurs
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU3401093A (en) Therapeutic agent for threatened abortion
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
IL112668A (en) 4-Amino 6-substituted mycophenolic acid and derivatives thereof their preparation and pharmaceutical compositions containing them
EP1034790A3 (fr) Thérapie pour HIV
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
WO1999006438A3 (fr) Composes a activite anti-sk et anti-vih
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
IL144382A0 (en) HIV-1 MUTATIONS SELECTED FOR BY β-2',3'-DIDEHYDRO-2',3-DIDEOXY-5-FLUROCYTIDINE
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent
James 1592--new experimental antiretroviral
EP1731155A3 (fr) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine pour l'utilisation dans le traitement d'une infection par le hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase